From artificial intelligence to military defense, China has offered a few DeepSeek moments this year, showcasing that the country is more than just the world’s biggest factory, and that it also can compete with the US on the technology front. Now biotech is having its own.
In late May, Pfizer Inc. agreed to pay a record $1.25 billion upfront to license an experimental cancer drug from Shenyang-based 3SBio Inc., as well as making a $100 million equity investment in the Hong Kong-listed biotech company. Two weeks later, Bristol-Myers Squibb Co. said it would pay BioNTech SE $1.5 billion guaranteed to license a ...
